CN1535652A - Non-invasion medicine hepatoxic monitoring instrument system and its application - Google Patents
Non-invasion medicine hepatoxic monitoring instrument system and its application Download PDFInfo
- Publication number
- CN1535652A CN1535652A CNA031094791A CN03109479A CN1535652A CN 1535652 A CN1535652 A CN 1535652A CN A031094791 A CNA031094791 A CN A031094791A CN 03109479 A CN03109479 A CN 03109479A CN 1535652 A CN1535652 A CN 1535652A
- Authority
- CN
- China
- Prior art keywords
- parameter
- blood pressure
- medicine
- variable quantity
- point
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Abstract
The present invention relates to a non-invasive monitoring instrument system for medicamentous hepatargy and its application for monitoring hepatargy or hepatic dysfunction due to medicine.
Description
Technical field
The present invention relates to be used for the non-invasive monitoring instrument system of use in medicament-induced hepatotoxicity, with and be used to monitor liver toxicity or the abnormal purposes of liver function that is caused because of medicine.
Background technology
The existing in recent years trend of senescence gradually of world population increases along with suffering from the senile chronic disease population, and each pharmaceutical factory, whole world new drug that releases one after another is to improve its quality of the life.Yet the new drug that has much gone on the market or be about to go on the market is but prohibited the punishment of selling because a few patients acute liver side effect (the lighter's withdrawal, weight person carries out liver transplantation, heavier person's death) occurs recently.Because the sudden liver side effect of this kind is relevant with special body constitution of patient or multiple drug interaction, and its incidence rate extremely low (generally being lower than 0.1%), doctor or patient there is no religious services or rituals precognition earlier, and the pharmaceutical factory also can't detect during carrying out clinical trial.In order to safeguard only a few patient's life security, and must recall one, the real predicament that is met with for medical profession at the moment to the medicable new drug of most patient.
Medical profession is still felt simply helpless for acute liver side effect at present.During new drug development, the pharmaceutical factory can utilize animal and human trial to assess the liver toxicity of this medicine, has only low hepatotoxic medicine just can apply for and get permission listing usually.But the assessment experiment of this kind liver toxicity has its limitation, and general liver toxicity experiment is only reacted with the liver function of other medicines and time spent at this medicine or this medicine and measured.Yet, may take various other simultaneously new drug listing back patient and not be included in the medicine of former clinical trial, thereby cause the side effect that can't expect.In addition, patient's number of clinical trial is calculated according to acute liver poisoning case incidence rate 0.1% generally in tens of, hundreds of or thousands of people's scope, does not reach on 1,000 people's the human trial statistics acute liver poisoning case to occur, even 10,000 people's test also just has ten acute cases.This kind is lower than 1% special case, general clinical effectiveness all with " reason is not bright " be that reason is rejected the scope of discussing in normal analysis, therefore do not abandon the chance of this medicine listing.The Glucovance Rezulin that the big pharmaceutical factory Pfizer of the U.S. recalls recently, about 1,000,000,000 yuan of original annual value of production Da Meijin, take patient 1,000,000 nearly, but in the liver poisoning case back (tens of people's death or liver transplantation) taking place recalls according to united states drug control food office regulation, original investment in research and development and follow-up losses such as suit for damages are all in hundred million yuan on U.S. dollar.As seen use in medicament-induced hepatotoxicity not only causes pharmaceutical factory profit on sales loss, but also must bear huge lawsuit damages.
United States Patent (USP) the 5th, 730 utilizes for No. 138 kit to measure patient's arteriotony fluctuation, and calculates each harmonic frequency corresponding to the heartbeat fundamental frequency with Fu Lier transformation approach (Fourier Transform).This United States Patent (USP) and the first harmonic of declaring gained are represented the blood circulation situation and the function thereof of liver, and other harmonic wave is then represented other organ of health.Yet the purpose of this case mainly is to diagnose the patients'blood blood circulation, and for the liver function of judging this patient just often whether it must compare its liver harmonic characterisitic and normal person.
Above-mentioned prior art does not disclose or advises how preventing drug-induced acute liver side effect.The pharmaceutical factory is for reducing acute liver side effect generation case at present, often require patient every month or blood drawing every other month, the execution liver function detects, this detection generally include liver ferment in the blood (AST[claims not only SGOT], ALT[but claim SGPT]) and the measurement of bilixanthin (Bilirubin).When one of this three numerical value is higher than normal value and reaches certain level the 2-3 of normal value (be generally doubly), the doctor just indicates patient to discontinue medication, because acute liver poisoning can take place in a few days or a few weeks longer, monthly or every other month check, though can reduce the case number, but can't effectively restrain, the blood liver function test not only improves medical treatment cost in addition, and causes many miseries of the patient that takes medicine (blood drawing) and inconvenience (check waits back and forth).
Summary of the invention
The inventor finds, utilizes non-intrusion type pressure inductor and instrument system thereof, can record the blood pressure pulse baseline before patient takes medicine and the blood pressure pulse wave mode of period in a medicine and change.The characteristic of this change can record when this medicine clinical experiment.The inventor further finds, as long as the change amount of this blood pressure wave mode characteristic of regular monitoring period in a medicine, can record in early days just whether patient's liver during taking medicine is poisoned or pathological changes such as inflammation.Owing to after medicine enters human body, must just can excrete via liver decomposition or conversion usually, if medicine is to hepatocyte toxigenicity or destruction, cause inflammation, the blood flow that then flows to the liver tremulous pulse can be than many under the normal condition, so that new oxygen demand to be provided, and support liver cell regeneration.In addition, the portal vein that poisoning, inflammation and the hepatocyte and the surrounding tissue thereof of enlargement can cause the inner resistance of blood flow of liver to increase, guiding the intestines and stomach venous blood enter liver rises because of the smooth generator gate vein hypertension (PortalHypertension) of path and epigastric vein bed (Splanchnic Venous bed) pressure.For alleviating the blood pressure of rising, autonomic nervous system and regional organization's cell soon discharge blood vessel expansion factor (Vasodilating factors), cause peripheral blood vessel to expand, because human vein and arterial system are the center with the heart, interconnects, form the loop, more than every hemodynamic change, all can cause the correspondence of arteriotony wave mode to change, therefore the measurement of arteriotony wave mode and the monitoring of change amount thereof, can be used as the theory and the technical foundation of the acute liver side effect prevention of medicine, and the characteristic and the scope thereof of blood pressure wave mode change amount, can record via medicine human clinical experimental result, and in view of the above under which kind of situation of standard liver function be unusual, should promptly provide alert or stop to take medicine.The present invention judges whether liver function is unusual, is that the change of the blood pressure wave mode before and after taking medicine according to this patient compares, but not compares with other normal person.In addition, it is to use at home that system and device of the present invention can be convenient to, and the gained data can see through various transmission means (phone, network, wireless telecommunications etc.) and reach the doctor place, therefore except that reducing the medical treatment cost, also can reduce the painful and inconvenient of patient.
Be the side effect that prevents that acute liver poisoning from producing, the invention provides a kind of patient of making during drug administration, can monitor the apparatus and method of its liver function at any time.Because but this device patients uses at home, and can promptly find and provide alert, thereby can reach function and the purpose that prevents that serious liver poisoning case from taking place at liver side effect early period of origination.
The present invention relates to a kind of be used to monitor use in medicament-induced hepatotoxicity or the abnormal Noninvasive instrument system of liver function, it comprises:
(a) measure the induction apparatus of arteriotony pulse, and produce the electric wave of representing blood pressure pulse; And
(b) acceptance is from the analyzer of the electric wave of (a), and it can calculate wave mode parameter (comprising crest number, main wave crest point, main trough point, subwave peak dot and/or subwave valley point), time parameter, pressure parameter, oblique angle parameter, area parameters and/or the scale parameter of this electric wave according to mathematical formulae.
Preferably, described induction apparatus is pressure inductor or one or more electrode slice.
Preferably, described pressure inductor is to wear in wrist and measure the device of the blood pressure pulse of hands radial artery.
Preferably, described analyzer further comprises a display, and it can show analytical data and the result who is embedded in the analyzer.
Preferably, described analyzer comprises that an alarm device is to send warning message.
Preferably, described analyzer further comprises the information transmission that can measure and analyze the gained result device to hospital or doctor's end, and this device further comprises can receiving by hospital or doctor and holds institute's information transmitted.
Preferably, described information is transmitted by wired or wireless mode.
The invention still further relates to a kind of be used to monitor use in medicament-induced hepatotoxicity or the abnormal Noninvasive instrument system of liver function, it comprises:
One wrist formula blood pressure pulse measurer, it utilizes the pressure sensitive assembly to convert the blood pressure pulse of patient's hands radial artery to wave mode parameter (comprising crest number, main wave crest point, main trough point, subwave peak dot and/or subwave valley point), time parameter, pressure parameter, oblique angle parameter, area parameters and/or scale parameter;
One bedside record analysis device can receive, amplifies, filtration and analog-digital conversion be from the electric wave of blood pressure pulse measurer, and wherein this analyzer comprises a minicomputer, is responsible for the recording blood pressure pulse and analyzes frequency, amplitude and the phase angle of liver harmonic wave; And
One information server and terminating machine, can with from the transfer of data of analyzer to hospital or clinic for doctor's interpretation, and the passback doctor indicate bedside record analysis device to patient end.
The invention further relates to a kind of liver toxicity or abnormal method of liver function that is used to monitor the medicine initiation, this method comprises: utilize described instrument system to detect and calculate wave mode parameter (comprising crest number, main wave crest point, main trough point, subwave peak dot and/or subwave valley point), time parameter, pressure parameter, oblique angle parameter, area parameters and/or the scale parameter of blood pressure pulse respectively in the front and back of drug administration; If before and after the drug administration, wherein this variable quantity arbitrary or some parameter value is lower than a certain predetermined value, represents that this medicine does not cause the liver function side effect; If wherein should be arbitrary or the variable quantity of some parameter value between certain two predetermined value, represent that medicine has caused the changes of liver function of certain degree; If wherein this variable quantity arbitrary or some parameter value is higher than certain predetermined value, the expression medicine has caused serious changes of liver function.
Description of drawings
Fig. 1 shows the sketch map of the preferred embodiment of the invention.
Fig. 2 shows normal staff radial artery blood pressure wave mode example.
Fig. 3 shows normal person in middle and old age's staff radial artery blood pressure wave mode example.
Fig. 4 shows acute hepatitis patient hands radial artery blood pressure wave mode example.
Fig. 5 shows the forward foot in a step arteriotony wave mode (preceding-datum line of not taking medicine) of numbering A Canis familiaris L..
Fig. 6 shows the forward foot in a step arteriotony wave mode (taking medicine back 12 hours) of numbering A Canis familiaris L..
Fig. 7 shows the forward foot in a step arteriotony wave mode (preceding-datum line of not taking medicine) of numbering B Canis familiaris L..
Fig. 8 shows the forward foot in a step arteriotony wave mode (taking medicine back 12 hours) of numbering B Canis familiaris L..
Fig. 9 shows the blood pressure wave mode of code name patient A period of disease.
Figure 10 shows the blood pressure wave mode after code name patient A restores.
Figure 11 shows the blood pressure wave mode of code name patient B period of disease.
Figure 12 shows the blood pressure wave mode after code name patient B restores.
The specific embodiment
The present invention relates to a kind of Noninvasive commercial measurement liver toxicity or abnormal instrument system of liver function utilized, it comprises that mainly (a) measures the induction apparatus of arteriotony pulse, and produces the electric wave of representing blood pressure pulse; And (b) accept analyzer from the electric wave of (a), it can (comprise the crest number, main wave crest point according to the wave mode parameter that mathematical method calculates this electric wave, main trough point, subwave peak dot and/or subwave valley point), time parameter, pressure parameter, oblique angle parameter, area parameters and/or scale parameter.
According to instrument system of the present invention, can utilize known mathematical formula and certain computer software or human brain interpretation and calculating, learn each parameter of general normal person's hands radial artery blood pressure wave mode as shown in Figure 2, comprise wave mode parameter (crest number, main wave crest point, main trough point, the subwave peak dot, the subwave valley point), time parameter (T1 to T6), pressure parameter (P1 to P6), oblique angle parameter (D1 to D9), area parameters (A1 to A10), and scale parameter (RT1 to RT5, RP1 to RP2, RA1 to RA5) etc.Hands radial artery blood pressure ripple is the one-period ripple, its general wave mode characteristic can be explained according to known physiology and hematodinamics earlier, the starting point of blood pressure wave mode (the A point of Fig. 2) is as atrium (Atria) when beginning to shrink, the minor fluctuations that this contraction causes only just can be observed when youngster or testee have elastomeric tremulous pulse and heart valve.After atrial systole, ventricle (Ventricles) and then also shrinks, and penetrates blood rapidly by large artery trunks (Aorta).At this moment, the blood pressure ripple is ascendant trend (A to B point) rapidly, and the B point is represented the main peak point of wave mode, also is the maximum of blood pressure ripple, is commonly referred to as systolic pressure (Systolic Pressure).Because large artery trunks is Elastic tissue, high pressure blood by the time enlarge rapidly, but when penetrating blood (C point) when finishing, its elasticity causes that blood vessel is slightly counter to contract, and the secondary peak (D point) of generation wave mode.Ve finishes, large artery trunks valve (heart valve between ventricle and the large artery trunks, Aortic Valve) closes (E point suddenly, be called Dicrotic Notch again), the blood that prior partial flows to ventricle is cut off, bump large artery trunks valve, and be back to large artery trunks, cause blood pressure to rise once more, and produce the 3rd ripple (F point).After this, heart continues lax, and blood flow flow to tremulous pulse and branch thereof from large artery trunks gradually, and blood pressure also continues to descend, and arrives minimum point (G), and the G point is also referred to as diastolic pressure (Diastolic Pressure).The G point of Fig. 2 is the starting point of next heart beating or blood pressure ripple, just equals the A point of a ripple, and from then on the blood pressure ripple repeats not stop once more.
Fig. 3 then shows general normal person in middle and old age's staff radial artery blood pressure wave mode, the main difference of itself and Fig. 2 is in secondary peak (between the CDE of Fig. 2 or the BC of Fig. 3 point) not obvious, only present a small shoulder type fluctuation, this is because the event that the arterial elasticity of middle-aged and elderly people descends for general deduction, also therefore, the crest number is kept to 2 by 3, except that this, parameters still can clearly define and calculate, as shown in Figure 3.Improper blood pressure wave mode is of a great variety, Fig. 4 shows the hands radial artery blood pressure wave mode of an acute hepatitis case gained, this patient's crest number has been reduced to one, except the main crest of a broadness, the fluctuation that is produced after the large artery trunks valve is closed only forms shoulder type fluctuation, but not a near crest (the C point), yet every wave mode parameter still can clearly define and calculate.
The liver toxicity or the liver function of indication of the present invention are undesired, the general index of judging that the liver function the subject of knowledge and the object of knowledge detects of general reference, serum glutaric acid oxalic acid transaminase (SGOT for example, claim AST again), serum paddy acetone acid transaminase (SGPT, claim ALT again), alkali phosphatase (ALK-P), glutaric acid change sour enzyme numerical value such as (r-GT), is higher or lower than the general standard value person that those who familiarize themselves with the technology is assert.For example, the standard value of SGPT is 0 to 40, when the SGPT value is higher, and situations such as the acute, chronic hepatitis that expressed possibility, alcoholic hepatopathy, liver cirrhosis.
According to the present invention, wherein the induction apparatus of this measurement arteriotony pulse can be, but the non-pressure inductor that is limited to.This pressure inductor can be any known induction apparatus that is used to measure blood pressure pulse, for example utilizes the induction apparatus of piezoelectric patches (Pressure Sensor) or tension measurement instrument (Strain Gauge).And the structure of piezoelectric patches can be, but non-pressure resistance type (Piezo-resistive) or the piezoelectric type (Piezo-electrical) of being limited to.This induction apparatus can be and is fit to place each position skin surface of patient and measures arterial pulse person, for example: head, cervical region, finger, wrist, arm and thigh portion, or shoulder, thigh, shank, positions such as foot wherein are preferably and wear in wrist and measure the device of the blood pressure pulse of hands radial artery.
According to the present invention, wherein this accepts the analyzer of self-inductor electric wave can be, but non-ly is limited to general minicomputer or oscillograph, and includes the software and hardware assembly, and it can be received the blood pressure pulse signal that passes self-inductor, store, analyze and show.This analyzer system can utilize any prior art method people (1995) or No. 363404 described persons of patent of Republic of China's notification number such as people (1987), Yang such as (for example) De Boer with the measured blood pressure pulse of induction apparatus, with known mathematical formula and particular software application, calculate as Fig. 2, Fig. 3, and each wave mode parameter shown in Figure 4, time parameter, pressure parameter, the oblique angle parameter, area parameters, scale parameter, and the clear and definite mathematical definition of other tool can be qualitative or parameters such as wave mode characteristic that quantitative description is measured.Preferably, the variation of the frequency of each parameter that reaches period in a medicine blood pressure wave mode before patient takes medicine can be noted down and be compared to this component software.
According to the present invention, wherein this analyzer further comprises a display, and it can show analytical data and the result who is embedded in the analyzer.This display panel can be, but is not defined as liquid crystal display LCD, oscillograph, digital display board LED (Light-emitting diode), computer display CRT (cathode-ray tube) or printer.
According to the present invention, wherein this analyzer further comprises the information transmission that can measure and analyze the gained result device to hospital or doctor's end, and this device further comprises can receiving by hospital or doctor and holds institute's information transmitted.This information carrying means can transmit information by wired or wireless mode, and it can be transmission means such as phone, network satellite and wireless telecommunications.
According to the present invention, if in case of necessity, this analyzer can have the alarm device of the signal of the warning of sending.This alarm signal can be the signal of sound or vision.Result that this alarm device can be analyzed according to analyzer or hospital or doctor institute information transmitted are sent alarm signal.This alarm device can be, but be not defined as sound, literal or figure or flashing lamp etc. on the display.
According to the preferred enforcement embodiment of monitoring use in medicament-induced hepatotoxicity of the present invention or the abnormal Noninvasive instrument system of liver function, it comprises:
One wrist formula blood pressure pulse measurer, it utilizes the pressure sensitive assembly to convert the blood pressure pulse of patient's hands radial artery to the wave mode parameter (to comprise the crest number, main wave crest point, main trough point, subwave peak dot and/or subwave valley point), time parameter, pressure parameter, the oblique angle parameter, area parameters and/or scale parameter;
One bedside record analysis device can receive, amplifies, filtration and analog-digital conversion be from the electric wave of blood pressure pulse measurer, and wherein this analyzer comprises a minicomputer, is responsible for the recording blood pressure pulse and analyzes frequency, amplitude and the phase angle of liver harmonic wave; And
One information server and terminating machine, can with from the transfer of data of analyzer to hospital or clinic for doctor's interpretation, and the passback doctor indicate bedside record analysis device to patient end.
The present invention provides a kind of liver toxicity or abnormal method of liver function that medicine causes that be used to monitor in addition, the wave mode parameter that its front and back that are included in drug administration utilize instrument system of the present invention to detect and calculate blood pressure pulse respectively (comprises the crest number, main wave crest point, main trough point, subwave peak dot and/or subwave valley point), time parameter, pressure parameter, the oblique angle parameter, area parameters and/or scale parameter; If before and after the drug administration, wherein this variable quantity arbitrary or some parameter value is lower than a certain predetermined value, represents that this medicine does not cause the liver function side effect; If wherein should be arbitrary or the variable quantity of some parameter value between certain two predetermined value, represent that medicine has caused the changes of liver function of certain degree; If wherein this variable quantity arbitrary or some parameter value is higher than certain predetermined value, the expression medicine has caused serious changes of liver function.
According to the preferred embodiment of the present invention, via under show that step can monitor effectively and prevent that medicine from causing the abnormal generation of patient's liver function:
(I) regularly measure each characteristic parameter value that reaches the blood pressure wave mode of period in a medicine before the patient takes medicine, regular measurement wherein can be between every day, jede Woche or other given period;
(II) according to gained data in the step (I), calculate take medicine after caused liver function change, this change comprise take medicine before and after wave mode parameter in the blood pressure wave mode, time parameter, pressure parameter, oblique angle parameter, the variation of area parameters and/or scale parameter; And
(III) data variation measured in the step (II) is defined as three kinds of scopes according to the clinical experiment result:
Be lower than certain special value and represent that this medicine presents normal effect;
This medicine of expression has caused that liver function changes, and answers monitor closely, and patient and/or doctor are sent early warning between certain two numerical value; And
The change that is higher than certain numeric representation liver function that this medicine causes has had a strong impact on patient health, should discontinue medication at once.
According to instrument system of the present invention and method, can be convenient to for user at home, but the patient detect in a continuous manner every day, the information carrying means that the gained data can see through in the analyzer reach the doctor place, so that the doctor understands patient's situation, and can further do suitable disposal.The of the present invention one preferred embodiment of implementing is shown in the sketch map of Fig. 1, for this instrument system comprises a wrist formula blood pressure pulse measurer, it utilizes the pressure sensitive assembly to convert the blood pressure pulse of patient's hands radial artery to electric wave, this electric wave signal is through amplifying, after filtration and the analog-digital conversion, reach bedside record analysis device, this analyzer contains a minicomputer, be responsible for the recording blood pressure pulse, analyze each characteristic parameter value of representing liver function, and data is revealed on the display panel of analyzer and transfers to hospital or clinic, and the patient information server of hospital or clinic end and terminating machine are responsible for patient end and are transmitted recording of information, analyse and compare and the passback doctor indicate bedside record analysis device to patient end.
According to monitoring system of the present invention, when new drug carries out the human clinical trial, patient Yu take medicine preceding and take medicine during all carry out blood liver function (AST and ALT liver ferment; Also can add and survey bilixanthin) check, also carry out blood pressure pulse simultaneously and measure.If (for example AST and ALT raise for blood test data and blood pressure pulse data tool height association, represent liver inflammation or poisoning and the also rising of correspondence ground or the reduction of some characterisitic parameter of blood pressure wave mode), then these data can be offered health competent authority, to obtain the permission that the non-invasion blood pressure pulse volume measures generation (or every other month) blood testing in every month.When new drug goes on the market, the patient that takes medicine only needs using monitoring system of the present invention at home every day, day by day compare each parameter value, when parameter value surpasses the scope of normal value and reaches certain numerical value (determining according to clinical data) by pharmaceutical factory and doctor, monitoring system is promptly sent alarm signal, require patient's withdrawal, and carry out the whole livers functional check immediately.
Above-mentioned various instruments, equipment and the assemblies etc. that are used for instrument system of the present invention, only for reaching the example of required function, other similar assembly if can reach identity function person, all can be applicable in the instrument system of the present invention.For example measure the human blood-pressure pulse, also can other tremulous pulse amount beyond the hands radial artery get.And for example bedside record analysis device also can see through the software of device in advance, and the warning of side effect directly is provided, and does not need patient data is reached hospital/clinic.Each wave mode parameter-definition shown in Fig. 2,3 and 4 and for example only is tangible example, and the clear and definite mathematical definition of other tool can qualitative or quantitative description blood pressure wave mode and variation person thereof, all can be used as the parameter of monitoring.
Show that embodiment further specifies exploitativeness of the present invention below existing, make the technology of the present invention content more concrete, right non-ly desire to limit to scope of the present invention.Other is familiar with this operator based on the teaching of known skill and attainable many variations of the present invention and improvement all should belong to category of the present invention.
Example 1: medicine changes the experiment of the monitoring-Canis familiaris L. of liver function
Two of adult dog weigh 12 and 15 kilograms, and wherein first (numbering A) accepts acetamido phenol (Acetaminophen) oral liquid (soluble in water) of 500 milligrams/kg body weight; Second (numbering B) then accepts the hypodermic dosage of acetamido phenol of higher (1200 milligrams/kg body weight), at injecting narcotic (Nembutal) and after connecting respiratory aid, the forward foot in a step of Canis familiaris L. cut to operate on behind the hair insert the arteriotony induction apparatus.The forward foot in a step (Brachial Position) arteriotony wave mode 100 data of per minute is in a continuous manner noted down and is analyzed via computer, every Canis familiaris L. after operation but do not take or injectable drug before measure two hours blood pressure wave mode earlier, as datum line (Baseline), take or injectable drug after, prison is recorded the blood pressure wave mode continuously again, with analysis as use in medicament-induced hepatotoxicity, in addition from arterial cannulation, regularly taking out blood is analyzed, to judge hepatotoxic degree, the following tabulation 1 of experimental result is extremely shown in Figure 8 to table 8 and Fig. 5.
Table 1: numbering A Sanguis Canitis liquid assay
| Experimental condition | Datum line | After the dispenser 1 hour | After the dispenser 6 hours | After the dispenser 12 hours |
| AST (SGOT); The IU/ liter | 37 | 35 | 33 | 45 |
| ALT (SGPT); The IU/ liter | 28 | 25 | 23 | 24 |
| Total bilixanthin MG/DL | 0.2 | 0.3 | 0.2 | 0.2 |
Table 2: the blood pressure wave mode of numbering A Canis familiaris L. (before not taking medicine-and datum line) each parameter value analysis result
| The wave mode parameter | Time parameter (second) | Pressure parameter (mmHg) | Oblique angle parameter (mmHg/ second) | Area parameters (second * mmHg) | Scale parameter |
| Crest number=2 | T1＝ab＝0.06 | ?P1＝Aa＝148 | D1＝(Bb-Aa)/ab＝7 50 | A1＝AabB＝10 | RT1＝ab/ae＝0.16 |
| Main wave crest point=B | T2＝bc＝0.10 | ?P2＝Bb＝193 | D2＝(Bb-Cc)/bc＝3 90 | A2＝BbcC＝17 | RT2＝ac/ae＝0.42 |
| Main trough point=A or E | T3＝cd＝0.05 | ?P3＝Cc＝154 | D3＝(Dd-Cc)/cd＝3 00 | A3＝CcdD＝8 | RT3＝ad/ae＝0.55 |
| Subwave peak dot=D | T4＝de＝0.17 | ?P4＝Dd＝169 | D4＝(Dd-Ee)/de＝1 20 | A4＝DdeE＝27 | RP1＝Dd/Bb＝0.98 |
| Subwave valley point=C | T5＝ae＝0.38 | ?P5＝Ee＝148 | D5＝D1+D2＝1140 | A5＝A1+A2＝27 | RA1＝A6/A5＝1.30 |
| D6＝D3+D4＝420 | A6＝A3+A4＝35 | RA2＝A5/A7＝0.44 | |||
| A7＝A5+A6＝62 | RA3＝A6/A7＝0.56 |
Table 3: each parameter value analysis result of blood pressure wave mode (taking medicine back 12 hours) of numbering A Canis familiaris L.
| The wave mode parameter | Time parameter (second) | Pressure parameter (mmHg) | Oblique angle parameter (mmHg/ second) | Area parameters (second * mmHg) | Scale parameter |
| Crest number=2 | T1＝ab＝0.05 | P1＝Aa＝149 | ?D1＝(Bb-Aa)/ab＝92 | A1＝AabB＝9 | ?RT1＝ab/ae＝0.12 |
| Main wave crest point=B | T2＝bc＝0.11 | P2＝Bb＝195 | ?D2＝(Bb-Cc)/bc＝350 | A2＝BbcC＝19 | ?RT2＝ac/ae＝0.40 |
| Main trough point=A or E | T3＝cd＝0.04 | P3＝Cc＝156 | ?D3＝(Dd-Cc)/cd＝420 | A3＝CcdD＝7 | ?RT3＝ad/ae＝0.49 |
| Subwave peak dot=D | T4＝de＝0.21 | P4＝Dd＝173 | ?D4＝(Dd-Ee)/de＝110 | A4＝DdeE＝34 | ?RP1＝Dd/Bb＝0.89 |
| Subwave valley point=C | T5＝ae＝0.41 | P5＝Ee＝149 | ?D5＝D1+D2＝1270 | A5＝A1+A2＝28 | ?RA1＝A6/A5＝1.46 |
| ?D6＝D3+D4＝530 | A6＝A3+A4＝41 | ?RA2＝A5/A7＝0.41 | |||
| A7＝A5+A6＝69 | ?RA3＝A6/A7＝0.59 |
Table 4: each parameter variable quantity analysis result before and after the blood pressure wave mode of numbering A Canis familiaris L. is taken medicine
| The wave mode parameter | Time parameter | Pressure parameter | The oblique angle parameter | Area parameters | Scale parameter |
| Variable quantity (second) | Variable quantity (mmHg) | Variable quantity (mmHg/ second) | Variable quantity (second * mmHg) | Variable quantity | |
| Crest number=2 | T1＝ab＝-16.7 | P1＝Aa＝0.7 | D1＝(Bb-Aa)/ab＝22.7 | A1＝AabB＝-10.0 | ?RT1＝ab/ae＝-25.0 |
| Main wave crest point=B | T2＝bc＝10.0 | P2＝Bb＝1.0 | D2＝(Bb-Cc)/bc＝-10.2 | A2＝BbcC＝11.8 | ?RT2＝ac/ae＝-5.0 |
| Main trough point=A or E | T3＝cd＝-20.0 | P3＝Cc＝1.3 | D3＝(Dd-Cc)/cd＝40.0 | A3＝CcdD＝-12.5 | ?RT3＝ad/ae＝-11.0 |
| Subwave peak dot=D | T4＝de＝23.5 | P4＝Dd＝2.4 | D4＝(Dd-Ee)/de＝-8.3 | A4＝DdeE＝25.9 | ?RP1＝Dd/Bb＝9.2 |
| Subwave valley point=C | T5＝ae＝7.9 | P5＝Ee＝0.7 | D5＝D1+D2＝11.4 | A5＝A1+A2＝3.7 | ?RA1＝A6/A5＝12.3 |
| D6＝D3+D4＝26.2 | A6＝A3+A4＝17.1 | ?RA2＝A5/A7＝-6.8 | |||
| A7＝A5+A6＝11.3 | ?RA3＝A6/A7＝5.3 |
The parameter variable quantity is defined as: (the back parameter value-preceding parameter value of taking medicine of taking medicine)/parameter value * 100% before taking medicine
Table 5: numbering B Sanguis Canitis liquid assay
| Experimental condition | Datum line | After the dispenser 1 hour | After the dispenser 6 hours | After the dispenser 12 hours |
| AST (SGOT); The IU/ liter | 41 | 38 | 198 | 298 |
| ALT (SGPT); The IU/ liter | 32 | 33 | 37 | 47 |
| Total bilixanthin MG/DL | 0.2 | 0.2 | 0.2 | 0.2 |
Table 6: the blood pressure wave mode of numbering B Canis familiaris L. (before not taking medicine-and datum line) each parameter value analysis result
| The wave mode parameter | Time parameter (second) | Pressure parameter (mmHg) | Oblique angle parameter (mmHg/ second) | Area parameters (second * mmHg) | Scale parameter |
| Crest number=3 | ?T1＝ab＝0.05 | P1＝Aa＝107 | D1＝(Bb-Aa)/ab＝860 | A1＝AabB＝6.4 | RT1＝ab/ag＝0.07 |
| Main wave crest point=B | ?T2＝bc＝0.04 | P2＝Bb＝150 | D2＝(Bb-Cc)/bc＝680 | A2＝BbcC＝5.5 | RT2＝ac/ag＝0.13 |
| Main trough point=A or G | ?T3＝cd＝0.04 | P3＝Cc＝123 | D3＝(Dd-Cc)/cd＝250 | A3＝CcdD＝5.1 | RT3＝ad/ag＝0.19 |
| Subwave peak dot=D﹠F | ?T4＝de＝0.05 | P4＝Dd＝133 | D4＝(Dd-Ee)/de＝460 | A4＝DdeE＝6.1 | RT4＝ae/ag＝0.27 |
| Subwave valley point=C﹠E | ?T5＝ef＝0.05 | P5＝Ee＝110 | D5＝(Ff-Ee)/ef＝340 | A5＝EefF＝5.9 | RT5＝af/ag＝0.34 |
| ?T6＝fg＝0.45 | ?P6＝Ff＝127 | ?D6＝(Ff-Gg)/fg＝40 | A6＝FfgG＝52.7 | RP1＝Dd/Bb＝0.89 | |
| ?T7＝ag＝0.67 | ?P7＝Gg＝107 | ?D7＝D1+D2＝1540 | A7＝A1+A2＝11.9 | RP2＝Ff/Bb＝0.85 | |
| ?D8＝D3+D4＝710 | A8＝A3+A4＝11.2 | RA1＝A8/A7＝0.94 | |||
| ?D9＝D5+D6＝380 | A9＝A5+A6＝58.6 | RA2＝A9/A7＝4.92 | |||
| A10＝A7+A8+A9＝81.7 | RA3＝A7/A10＝0.14 | ||||
| RA4＝A8/A10＝0.14 | |||||
| RA5＝A9/A10＝0.72 |
Table 7: each parameter value analysis result of blood pressure wave mode (taking medicine back 12 hours) of numbering B Canis familiaris L.
| The wave mode parameter | Time parameter (second) | Pressure parameter (mmHg) | Oblique angle parameter (mmHg/ second) | Area parameters (second * mmHg) | Scale parameter |
| Crest number=2 | T1＝ab＝0.04 | ?P1＝Aa＝16 | D1＝(Bb-Aa)/ab＝2250 | A1＝AabB＝2.44 | RT1＝ab/ag＝0.17 |
| Main wave crest point=B | T2＝be＝0.06 | ?P2＝Bb＝106 | D2＝(Bb-Ee)/be＝1383 | A2＝BbeE＝2.58 | RT2＝ae/ag＝0.42 |
| Main trough point=A or G | T3＝ef＝0.05 | ?P3＝Ee＝23 | D3＝(Ff-Ee)/ef＝420 | A3＝EefF＝1.68 | RT3＝af/ag＝0.63 |
| Subwave peak dot=F | T4＝fg＝0.09 | ?P4＝Ff＝44 | D4＝(Ff-Gg)/Fg＝311 | A4＝FfgG＝2.70 | RP1＝Ff/Bb＝0.42 |
| Subwave valley point=E | T5＝ag＝0.24 | ?P5＝Gg＝16 | D5＝D1+D2＝3633 | A5＝A1+A2＝5.02 | RA1＝A6/A5＝0.87 |
| D6＝D3+D4＝731 | A6＝A3+A4＝4.38 | RA2＝A5/A7＝0.53 | |||
| A7＝A5+A6＝9.40 | RA3＝A6/A7＝0.47 |
Table 8: each parameter variable quantity analysis result before and after the blood pressure wave mode of numbering B Canis familiaris L. is taken medicine
| The wave mode parameter | Time parameter variable quantity (%) | Pressure parameter variable quantity (%) | Oblique angle parameter variable quantity (%) | Area parameters variable quantity (%) | Scale parameter variable quantity (%) |
| Crest number=2 | T1＝ab＝-20 | P1＝Aa＝-85 | ?D1＝(Bb-Aa)/ab＝162 | A1＝AabB＝-62 | RT1＝ab/ag＝143 |
| Main wave crest point=B | T2＝be＝-54 | P2＝Bb＝-25 | ?D2＝(Bb-Ee)/be＝349 | A2＝BbeE＝-85 | RT2＝ae/ag＝55 |
| Main trough point=A or G | T3＝ef＝0 | P3＝Ee＝-79 | ?D3＝(Ff-Ee)/ef＝23 | A3＝EefF＝-72 | RT3＝af/ag＝85 |
| Subwave peak dot=F | T4＝fg＝-80 | P4＝Ff＝-65 | ?D4＝(Ff-Gg)/Fg＝677 | A4＝FfgG＝-95 | RP1＝Ff/Bb＝-51 |
| Subwave valley point=E | T5＝ag＝-64 | P5＝Gg＝-85 | ?D5＝D1+D2＝211 | A5＝A1+A2＝-47 | RA1＝A6/A5＝123 |
| ?D6＝D3+D4＝92 | A6＝A3+A4＝-61 | RA2＝A5/A7＝89 | |||
| A7＝A5+A6＝-84 | RA3＝A6/A7＝-35 |
Annotate:
(1) the parameter variable quantity is defined as: (the back parameter value-preceding parameter value of taking medicine of taking medicine)/parameter value * 100% before taking medicine;
(2) D2 parameter variable quantity system with take medicine preceding parameter value (Bb-Ee)/be=308 with take medicine after
Parameter value D2 (=1383) relatively calculates and gets, to meet the definition of raw parameter variable quantity;
(3) D6 parameter variable quantity system relatively calculates and gets with the parameter value D9 (=380) before taking medicine and the back parameter value D6 (=731) that takes medicine, to meet the definition of raw parameter variable quantity;
(4) A2 parameter variable quantity system relatively calculates and gets with the parameter value A2+A3+A4 (=16.7) before taking medicine and the back parameter value A2 (=2.58) that takes medicine, to meet the definition of raw parameter variable quantity;
(5) A3 parameter variable quantity system relatively calculates and gets with the parameter value A5 (=5.9) before taking medicine and the back parameter value A3 (=1.68) that takes medicine, to meet the definition of raw parameter variable quantity;
(6) A4 parameter variable quantity system relatively calculates and gets with the parameter value A6 (=52.7) before taking medicine and the back parameter value A4 (=2.70) that takes medicine, to meet the definition of raw parameter variable quantity;
(7) A5 parameter variable quantity system relatively calculates and gets with the parameter value A1+A2+A3+A4 (=9.4) before taking medicine and the back parameter value A5 (=5.02) that takes medicine, to meet the definition of raw parameter variable quantity;
(8) A6 parameter variable quantity system relatively calculates and gets with the parameter value A8 (=11.2) before taking medicine and the back parameter value A6 (=4.38) that takes medicine, to meet the definition of raw parameter variable quantity;
(9) A7 parameter variable quantity system relatively calculates and gets with the parameter value A9 (=58.6) before taking medicine and the back parameter value A7 (=9.40) that takes medicine, to meet the definition of raw parameter variable quantity;
(10) RT2 parameter variable quantity system is with parameter value RT4 (=0.27) before taking medicine and after taking medicine
Parameter value RT2 (=0.42) relatively calculates and gets, to meet the definition of raw parameter variable quantity;
(11) RT3 parameter variable quantity system is with parameter value RT5 (=0.34) before taking medicine and after taking medicine
Parameter value RT3 (=0.63) relatively calculates and gets, to meet the definition of raw parameter variable quantity;
(12) RP1 parameter variable quantity system is with parameter value RP2 (=0.85) before taking medicine and after taking medicine
Parameter value RP1 (=0.42) relatively calculates and gets, to meet the definition of raw parameter variable quantity;
(13) RA1 parameter variable quantity system relatively calculates and gets with the preceding parameter value (A7+A8) of the taking medicine/A9 (=0.39) and the back parameter value RA1 (=0.87) that takes medicine, to meet the definition of raw parameter variable quantity;
(14) RA2 parameter variable quantity system relatively calculates and gets with the preceding parameter value (A7+A8) of the taking medicine/A10 (=0.28) and the back parameter value RA2 (=0.53) that takes medicine, to meet the definition of raw parameter variable quantity;
(15) RA3 parameter variable quantity system is with parameter value RA5 (=0.72) before taking medicine and after taking medicine
Parameter value RA3 (=0.47) relatively calculates and gets, to meet the definition of raw parameter variable quantity.
This can cause the liver poisoning side effect when testing the known excessive use of employed medicine acetamido phenol.Numbering A Canis familiaris L. system is with 500 milligrams/kilogram of oral feedings, because of digesting and assimilating effect through the intestines and stomach, its effective blood dosage is lower, can find out that from the blood test result of table 1 it is very slight to the toxicity that liver produces, on behalf of hepatotoxic AST (SGOT), ALT (SGPT) and bilixanthin, tool do not depart from datum line, and wherein AST (SGOT) (its rising may be hepatocyte inflammation or other necrocytosis) take medicine back 12 hours also only microlitre to 45 IU/ rise.The Fig. 5 before representative numbering A Canis familiaris L. is taken medicine and both the blood pressure wave modes of back 12 hours Fig. 6 of taking medicine there is no significantly and change, and both crest number averages are 2, and wave mode is close to identical.Similarly, blood pressure wave mode parameter (table 2) there is no significantly with back both difference (table 4) of parameter (table 3) of taking medicine and changes before numbering A Canis familiaris L. was taken medicine, list in each the parameter variable quantity in the table 4, only have a parameter variable quantity (oblique angle parameter D3) to reach 40%, all the other all are lower than this value.
On the contrary, numbering B Canis familiaris L. system because it absorbs good and higher blood effective dose, can find out that from hematological results (table 5) this dosage has caused the liver toxicity of certain degree with the same medicine of subcutaneous injection 1200mg/kg.AST (SGOT) rose to 298 (IU/ liters) from datum line 41 (IU/ liter) after 12 hours, ALT also rises to 47, because be the acute poisoning experiment, bilixanthin does not obviously increase as yet, blood pressure wave mode (Fig. 7) before taking medicine has produced significantly with the blood pressure wave mode (Fig. 8) of taking medicine back 12 hours and has changed, the crest number (clinical experience show its be important liver poisoning parameter one) also be kept to 2 from 3, blood pressure wave mode parameter (table 6) then significantly improves than numbering A Canis familiaris L. with back (table 7) both variable quantities (table 8) of taking medicine before taking medicine, list in each the blood pressure wave mode parameter in the table 8, there are six parameter variable quantities to surpass 100%, coincide with hematological results, the analysis of blood pressure wave mode and the generation that relatively is enough to monitor use in medicament-induced hepatotoxicity before and after this routine experiment confirm is taken medicine, and can propose to report to the police to the pill taker by this.
Example 2: the monitoring of use in medicament-induced hepatotoxicity-human clinical's experiment
Two of middle age patients after outpatient service and being in hospital, all are diagnosed as not clear medicine and cause acute hepatitis, wherein code name patient's A hepatitis degree is lighter, and its ALT (SGPT) is 120 (IU/ liters) when being admitted to hospital, after treatment and recuperation, 42 (IU/ liters) have been reduced to before leaving hospital, near normal value.This patient's physiological signal and blood test result are as shown in Table 9.
Table 9: code name patient A physiological signal and blood test result
| Experimental condition | Period of disease | After the recovery |
| Pulse (inferior/minute) | 76 | 65 |
| Systolic pressure (mmHg) | 110 | 105 |
| Diastolic pressure (mmHg) | 70 | 70 |
| Body temperature (℃; The ear temperature) | 36.5 | 36.0 |
| ALT (SGPT); The IU/ liter | 120 | 42 |
| Total bilixanthin MG/DL | 0.5 | 0.4 |
Another code name patient's B hepatitis degree is more serious, and its ALT is 603 (IU/ liters) when being admitted to hospital, and after treatment and recuperation, has reduced to 36 (IU/ liters) before leaving hospital, and near normal value, this patient's physiological signal and blood test result are as shown in Table 10.
Table 10: code name patient B physiological signal and blood test result
| Experimental condition | Period of disease | After the recovery |
| Pulse (inferior/minute) | 75 | 64 |
| Systolic pressure (mmHg) | 120 | 120 |
| Diastolic pressure (mmHg) | 80 | 80 |
| Body temperature (℃; The ear temperature) | 36.0 | 36.5 |
| ALT (SGPT); The IU/ liter | 603 | 36 |
| Total bilixanthin MG/DL | 2.5 | 0.3 |
Two patients also accept the non-invasion blood pressure wave mode in the while in hospital and measure, this measurement system contains a piezoelectric patches (pressure sensor who wears in hands radial artery place, the EPN model of U.S. Entran company), wrist formula physiological monitor (the contain air group Pu in piezoelectric patches air pressure source is provided, air valve, barometer, signal acquisition and processing, circuit, central processing unit, internal memory, reach assemblies such as wireless transmission, be the laboratory self-control), a PC computer (includes wireless receiving module, blood pressure wave mode signal receives, store and analysis software), and a LCD display.
The blood pressure wave mode of code name patient A period of disease (admission day records) and parameter thereof are shown in Fig. 9 and table ten one, this blood pressure wave mode is compared with general normal middle-aged and elderly people blood pressure wave mode (Fig. 3), having produced certain degree changes, but after recuperating in hospital, its wave mode (Figure 10 one) is near general normal wave mode, relatively the blood pressure wave mode parameter (table ten one) of this patient's period of disease with restore after parameter (table ten two), the difference (table ten three) that can find both tool to a certain degree changes, but from blood ALT when the highest (120 IU/ liters), the degree of hepatitis still belongs to slightly, when general clinicist is increased to the three to four-fold (and 90 to 130IU/ scopes that rise) of normal value at ALT, just can require patient to suspend and take medicine, and whether the strict hepatitis of observing fades away or continues and worsen, in listed each parameter of table ten three, High variation amount is 110% (oblique angle parameter D4), but pressure parameter variable quantity (1 to 8%) and scale parameter variable quantity (2 to 24%) still belong to low degree, the clinical data of this patient and other similar case shows, the blood pressure wave mode parameter variation of this kind degree has caused obvious liver poisoning, reply doctor and patient propose to report to the police, and consider to stop various medications.
Table 11: each parameter value analysis result of the blood pressure wave mode of code name patient A period of disease
| The wave mode parameter | Time parameter (second) | Pressure parameter (mmHg) | Oblique angle parameter (mmHg/ second) | Area parameters (second * mmHg) | Scale parameter |
| Crest number=2 | T1＝ab＝ 0.17 | P1＝Aa＝ 69 | D1＝(Bb-Aa)/ab ＝235 | A1＝AabB＝15 | RT1＝ab/ae＝ 0.22 |
| Main wave crest point=B | T2＝bc＝ 0.19 | P2＝Bb ＝109 | D2＝(Bb-Cc)/bc ＝100 | A2＝BbcC＝19 | RT2＝ac/ae＝ 0.46 |
| Main trough point=A or E | T3＝cd＝ 0.07 | P3＝Cc＝ 90 | D3＝(Dd-Cc)/cd ＝14 | A3＝CcdD＝6 | RT3＝ad/ae＝ 0.54 |
| Subwave peak dot=D | T4＝de＝ 0.36 | P4＝Dd＝ 91 | D4＝(Dd-Ee)/de ＝61 | A4＝DdeE＝29 | RP1＝Dd/Bb＝ 0.83 |
| Subwave valley point=C | T5＝ae＝ 0.79 | P5＝Ee＝ 69 | D5＝D1+D2＝335 | A5＝A1+A2＝34 | RA1＝A6/A5＝ 1.03 |
| D6＝D3+D4＝75 | A6＝A3+A4＝35 | RA2＝A5/A7＝ 0.49 | |||
| A7＝A5+A6＝69 | RA3＝A6/A7＝ 0.51 |
Table 12: each the parameter value analysis result of blood pressure wave mode after code name patient A restores
| The wave mode parameter | Time parameter (second) | Pressure parameter (mmHg) | Oblique angle parameter (mmHg/ second) | Area parameters (second * mmHg) | Scale parameter |
| Crest number=2 | T1＝ab＝0.17 | P1＝Aa＝70 | D1＝(Bb-Aa)/ab＝200 | A1＝AabB＝15 | RT1＝ab/ae＝0.18 |
| Main wave crest point=B | T2＝bc＝0.19 | P2＝Bb＝104 | D2＝(Bb-Cc)/bc＝111 | A2＝BbcC＝18 | RT2＝ac/ae＝0.39 |
| Main trough point=A or E | T3＝cd＝0.09 | P3＝Cc＝83 | D3＝(Dd-Cc)/cd＝11 | A3＝CcdD＝8 | RT3＝ad/ae＝0.49 |
| Subwave peak dot=D | T4＝de＝0.48 | P4＝Dd＝84 | ?D4＝(Dd-Ee)/de＝29 | A4＝DdeE＝37 | RP1＝Dd/Bb＝0.81 |
| Subwave valley point=C | T5＝ae＝0.92 | P5＝Ee＝70 | ?D5＝D1+D2＝311 | A5＝A1+A2＝33 | RA1＝A6/A5＝1.36 |
| ?D6＝D3+D4＝40 | A6＝A3+A4＝45 | RA2＝A5/A7＝0.42 | |||
| A7＝A5+A6＝78 | RA3＝A6/A7＝0.58 |
Table 13: each parameter variable quantity analysis result before and after code name patient's A the blood pressure wave mode hepatitis
| The wave mode parameter | Time parameter variable quantity (%) | Pressure parameter variable quantity (%) | Oblique angle parameter variable quantity (%) | Area parameters variable quantity (%) | Scale parameter variable quantity (%) |
| Crest number=2 | T1＝ab＝0 | P1＝Aa＝1 | D1＝(Bb-Aa)/ab＝18 | A1＝AabB＝0 | ?RT1＝ab/ae＝22 |
| Main wave crest point=B | T2＝bc＝0 | P2＝Bb＝5 | D2＝(Bb-Cc)/bc＝-10 | A2＝BbcC＝6 | ?RT2＝ac/ae＝18 |
| Main trough point=A or E | T3＝cd＝-22 | P3＝Cc＝8 | D3＝(Dd-Cc)/cd＝27 | A3＝CcdD＝-25 | ?RT3＝ad/ae＝10 |
| Subwave peak dot=D | T4＝de＝-25 | P4＝Dd＝8 | D4＝(Dd-Ee)/de＝110 | A4＝DdeE＝-22 | ?RP1＝Dd/Bb＝2 |
| Subwave valley point=C | T5＝ae＝-14 | P5＝Ee＝-1 | D5＝D1+D2＝8 | A5＝A1+A2＝3 | ?RA1＝A6/A5＝-24 |
| D6＝D3+D4＝88 | A6＝A3+A4＝-22 | ?RA2＝A5/A7＝17 | |||
| A7＝A5+A6＝-12 | ?RA3＝A6/A7＝-12 |
The parameter variable quantity is defined as: (period of disease parameter value-recovery back parameter value)/parameter value * 100% after restoring
The blood pressure wave mode of code name patient B period of disease (Figure 10 one and table ten four) and recovery back (Figure 10 two and table ten five) finds that through comparative analysis (table ten six) the liver poisoning degree is serious than code name patient A.Blood pressure wave mode crest number (represent the liver side effect important parameter one) two of reducing to period of disease of (promptly restore concerning back) from just often, in addition in each parameter variable quantity of table ten six, there are three to equal or exceed 100%, coincide with the trend of blood test, the clinical data of this patient and other similar case shows, the blood pressure wave mode parameter variation of this kind degree has caused serious liver side effect, should discontinue medication immediately, and receive treatment.
Table 14: each parameter value analysis result of the blood pressure wave mode of code name patient B period of disease
| The wave mode parameter | Time parameter (second) | Pressure parameter (mmHg) | Oblique angle parameter (mmHg/ second) | Area parameters * second mmHg) | Scale parameter |
| Crest number=2 | ?T1＝ab＝0.22 | P1＝Aa＝80 | D1＝(Bb-Aa)/ab＝182 | A1＝AabB＝22 | ?RT1＝ab/ad＝0.28 |
| Main wave crest point=B | ?T2＝bc＝0.13 | P2＝Bb＝120 | D2＝(Bb-Cc)/bc＝115 | A2＝BbcC＝15 | ?RT2＝ac/ad＝0.44 |
| Main trough point=A or D | ?T3＝cd＝0.45 | P3＝Cc＝105 | D3＝D1+D2＝297 | A3＝CcdD＝42 | ?RA1＝A3/A4＝1.14 |
| Subwave valley point=C | ?T4＝ad＝0.8 | P4＝Dd＝80 | A4＝A1+A2＝37 | ?RA2＝A4/A5＝0.47 | |
| A5＝A3+A4＝79 | ?RA3＝A3/A5＝0.53 |
Table 15: each the parameter value analysis result of blood pressure wave mode after code name patient B restores
| The wave mode parameter | Time parameter (second) | Pressure parameter (mmHg) | Oblique angle parameter (mmHg/ second) | Area parameters (second * mmHg) | Scale parameter |
| Crest number=2 | T1＝ab＝0.11 | ?P1＝Aa＝80 | D1＝(Bb-Aa)/ab＝364 | ?A1＝AabB＝11 | RT1＝ab/ae＝0.12 |
| Main wave crest point=B | T2＝bc＝0.23 | ?P2＝Bb＝120 | D2＝(Bb-Cc)/bc＝91 | ?A2＝BbcC＝25 | RT2＝ac/ae＝0.36 |
| Main trough point=A or E | T3＝cd＝0.07 | ?P3＝Cc＝99 | D3＝(Dd-Cc)/cd＝0 | ?A3＝CcdD＝7 | RT3＝ad/ae＝0.44 |
| Subwave peak dot=D | T4＝de＝0.53 | ?P4＝Dd＝99 | D4＝(Dd-Ee)/de＝36 | ?A4＝DdeE＝47 | RP1＝Dd/Bb＝0.83 |
| Subwave valley point=C | T5＝ae＝0.94 | ?P5＝Ee＝80 | D5＝D1+D2＝455 | A5＝A1+A2＝36 | RA1＝A6/A5＝1.5 |
| D6＝D3+D4＝36 | A6＝A3+A4＝54 | RA2＝A5/A7＝0.40 | |||
| A7＝A5+A6＝90 | RA3＝A6/A7＝0.60 |
Table 16: each parameter variable quantity analysis result before and after code name patient's B the blood pressure wave mode hepatitis
| The wave mode parameter | Time parameter variable quantity (%) | Pressure parameter variable quantity (%) | Oblique angle parameter variable quantity (%) | Area parameters variable quantity (%) | Scale parameter variable quantity (%) |
| Crest number=2 | T1＝ab＝100 | ?P1＝Aa＝0 | ?D1＝(Bb-Aa)/ab＝-50 | A1＝AabB＝100 | RT1＝ab/ad＝133 |
| Main wave crest point=B | T2＝bc＝-43 | ?P2＝Bb＝0 | ?D2＝(Bb-Cc)/bc＝26 | A2＝BbcC＝-40 | RT2＝ac/ad＝22 |
| Main trough point=A | T3＝cd＝-25 | ?P3＝Cc＝6 | ?D3＝D1+D2＝-40 | A3＝CcdD＝17 | RA1＝A3/A4＝-24 |
| Subwave valley point=C | T4＝ad＝-15 | ?P4＝Dd＝0 | A4＝A1+A2＝3 | RA2＝A4/A5＝18 | |
| A5＝A3+A4＝-12 | RA3＝A3/A5＝-12 |
Annotate:
(1) the parameter variable quantity is defined as: (period of disease parameter value-recovery back parameter value)/parameter value * 100% after restoring;
(2) T3 parameter variable quantity system is to restore back parameter value T3+T4 (=0.60) and period of disease
Parameter value T3 (=0.45) relatively calculates and gets, to meet the definition of raw parameter variable quantity;
(3) T4 parameter variable quantity system relatively calculates and gets with period of disease parameter value T3 (=0.80) to restore back parameter value T5 (=0.94), to meet the definition of raw parameter variable quantity;
(4) D3 parameter variable quantity system relatively calculates and gets with period of disease parameter value D3 (=297) to restore back parameter value D5 (=455), to meet the definition of raw parameter variable quantity;
(5) A3 parameter variable quantity system relatively calculates and gets with period of disease parameter value A3 (=42) to restore back parameter value A5 (=36), to meet the definition of raw parameter variable quantity;
(6) A4 parameter variable quantity system relatively calculates and gets with period of disease parameter value A4 (=37) to restore back parameter value A5 (=36), to meet the definition of raw parameter variable quantity;
(7) A5 parameter variable quantity system relatively calculates and gets with period of disease parameter value A5 (=79) to restore back parameter value A7 (=90), to meet the definition of raw parameter variable quantity.
Claims (9)
1. one kind is used to monitor use in medicament-induced hepatotoxicity or the abnormal Noninvasive instrument system of liver function, and it comprises:
(a) measure the induction apparatus of arteriotony pulse, and produce the electric wave of representing blood pressure pulse; And
(b) acceptance is from the analyzer of the electric wave of (a), and it can calculate wave mode parameter (comprising crest number, main wave crest point, main trough point, subwave peak dot and/or subwave valley point), time parameter, pressure parameter, oblique angle parameter, area parameters and/or the scale parameter of this electric wave according to mathematical formulae.
2. instrument system according to claim 1 is characterized in that described induction apparatus is pressure inductor or one or more electrode slice.
3. instrument system according to claim 2 is characterized in that described pressure inductor is to wear in wrist and measure the device of the blood pressure pulse of hands radial artery.
4. instrument system according to claim 1, this analyzer further comprises a display, and it can show analytical data and the result who is embedded in the analyzer.
5. instrument system according to claim 1 is characterized in that described analyzer comprises that an alarm device is to send warning message.
6. instrument system according to claim 1, it is characterized in that described analyzer further comprises the information transmission that can measure and analyze the gained result device to hospital or doctor's end, and this device comprises further can receiving by hospital or doctor and holds institute's information transmitted.
7. instrument system according to claim 6 is characterized in that described information transmits by wired or wireless mode.
8. one kind is used to monitor use in medicament-induced hepatotoxicity or the abnormal Noninvasive instrument system of liver function, and it comprises:
One wrist formula blood pressure pulse measurer, it utilizes the pressure sensitive assembly to convert the blood pressure pulse of patient's hands radial artery to wave mode parameter (comprising crest number, main wave crest point, main trough point, subwave peak dot and/or subwave valley point), time parameter, pressure parameter, oblique angle parameter, area parameters and/or scale parameter;
One bedside record analysis device, can receive, amplify, filtration and analog-digital conversion be from the electric wave of blood pressure pulse measurer, it is characterized in that described analyzer comprises a minicomputer, be responsible for the recording blood pressure pulse and analyze frequency, amplitude and the phase angle of liver harmonic wave; And
One information server and terminating machine, can with from the transfer of data of analyzer to hospital or clinic for doctor's interpretation, and the passback doctor indicate bedside record analysis device to patient end.
9. one kind is used to monitor liver toxicity or the abnormal method of liver function that medicine causes, and this method comprises: utilize wave mode parameter (comprising crest number, main wave crest point, main trough point, subwave peak dot and/or subwave valley point), time parameter, pressure parameter, oblique angle parameter, area parameters and/or the scale parameter of detecting and calculate blood pressure pulse according to claim 1 to 8 arbitrary described instrument system respectively in the front and back of drug administration; If before and after the drug administration, wherein this variable quantity arbitrary or some parameter value is lower than a certain predetermined value, represents that this medicine does not cause the liver function side effect; If wherein should be arbitrary or the variable quantity of some parameter value between certain two predetermined value, represent that medicine has caused the changes of liver function of certain degree; If wherein this variable quantity arbitrary or some parameter value is higher than certain predetermined value, the expression medicine has caused serious changes of liver function.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA031094791A CN1535652A (en) | 2003-04-09 | 2003-04-09 | Non-invasion medicine hepatoxic monitoring instrument system and its application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA031094791A CN1535652A (en) | 2003-04-09 | 2003-04-09 | Non-invasion medicine hepatoxic monitoring instrument system and its application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1535652A true CN1535652A (en) | 2004-10-13 |
Family
ID=34319364
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA031094791A Pending CN1535652A (en) | 2003-04-09 | 2003-04-09 | Non-invasion medicine hepatoxic monitoring instrument system and its application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1535652A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104207753A (en) * | 2013-02-15 | 2014-12-17 | 迈克尔·L·谢尔登 | Personal health monitoring system |
-
2003
- 2003-04-09 CN CNA031094791A patent/CN1535652A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104207753A (en) * | 2013-02-15 | 2014-12-17 | 迈克尔·L·谢尔登 | Personal health monitoring system |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6277072B1 (en) | System and method for monitoring a patient status for an individual patient using a reference baseline in an automated collection and analysis patient care system | |
| US9610012B2 (en) | System and apparatus for providing baseline data for automated patient management | |
| Hagins et al. | Effectiveness of yoga for hypertension: systematic review and meta-analysis | |
| TW524670B (en) | Non-invasive apparatus system for monitoring autonomic nervous system and uses thereof | |
| US7162294B2 (en) | System and method for correlating sleep apnea and sudden cardiac death | |
| US6203495B1 (en) | System and method for providing normalized voice feedback from an individual patient in an automated collection and analysis patient care system | |
| EP1072994A2 (en) | System and method for providing normalized voice feedback from an individual patient in an automated collection and analysis patient care system | |
| EP1107158B1 (en) | System and method for determining a reference baseline of individual patient status for use in an automated collection and analysis patient care system | |
| US7074190B2 (en) | Non-invasive apparatus system for monitoring drug hepatoxicity and uses thereof | |
| US20180203009A1 (en) | Device, system and method for managing treatment of an inflammatory autoimmune disease of a person | |
| Xing et al. | An artifact-resistant feature SKNAER for quantifying the burst of skin sympathetic nerve activity signal | |
| CN115867975A (en) | System and method for generating patient medical records | |
| Omvik et al. | The Norwegian office-, home-, and ambulatory blood pressure study (NOHA) | |
| CN1535652A (en) | Non-invasion medicine hepatoxic monitoring instrument system and its application | |
| Rubler et al. | Ambulatory blood pressure monitoring in diabetic males: a method for detecting blood pressure elevations undisclosed by conventional methods | |
| AU759934B2 (en) | System and method for determining a reference baseline of individual patient status for use in an automated collection and analysis patient care system | |
| EP1522257A1 (en) | Non-invasive apparatus system for monitoring drug hepatoxicity | |
| CN1444901A (en) | Injury-free and automatic type nerve system monitoring instrument system and its use | |
| CN113100775A (en) | Intelligent cardiovascular nursing monitoring system | |
| Trang et al. | THE ABILITY TO SELF-MANAGEMENT CARE AND A NUMBER OF RELATED FACTORS HYPERTENSION OUTPATIENT AT DUC GIANG GENERAL HOSPITAL IN 2020-2021 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |